Role of nanostructures in improvising oral medicine

DOI: 10.1016/j.toxrep.2019.04.004

Keywords: AD, Alzheimer’s disease, AmB, amphotericin B, AMCNS, cationic niosome-based azithromycin delivery systems, AP, acetylpuerarin, AT1R, angiotensin II receptor type 1, BCRP, breast cancer resistance protein, CNL, conventional lipid nanoparticles, CSC, core shell corona nanolipoparticles, DCK, N-deoxycholyl-l-lysyl-methylester, DDS, drug delivery system, DM, diabetes mellitus, DOX, doxorubicin, EPR, enhanced permeability and retention effect, FRET, Foster resonance energy transfer, 5-FU, 5-fluorouracil, GI, gastrointestinal, GMO, glyceryl monoolein, IBD, inflammatory bowel disease, LG, Lakshadi Guggul, LNC, Lipid Nanocapsule, MFS, Miltefosine, MNBNC, Micronucleated Binucleated Cells, MSN, mesoporous silica nanoparticle, MTX, methotrexate, NP, nanoparticle, NPC, nanoparticulate carriers, NSAID, non-steroidal anti-inflammatory drug, OA, osteoarthritis, OXA, oxaliplatin, PAMAM, poly (amidoamine), PD, Parkinson’s disease, PEG, polyethylene glycol, PIP, 1-piperoylpiperidine, PLGA, polylactic-co-glycolic acid, PNL, PEGylated lipid nanoparticles, pSi, porous silicon, pSiO, porous silica oxide, PZQ, praziquantel, SLN, solid lipid nanoparticle, SMA, styrene maleic acid, SMEDD, self microemulsifying drug delivery system, TB, tuberculosis, Tmf, tamoxifen, TNBS, trinitrobenzenesulphonic acid, TPGS, tocopheryl polyethylene glycol succinate, WGA, wheat germ agglutinin Oral medicine, Nanostructures, Drug delivery system

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text